The University of Chicago Header Logo

Connection

Hans Schreiber to Neoplasm Transplantation

This is a "connection" page, showing publications Hans Schreiber has written about Neoplasm Transplantation.
Connection Strength

0.706
  1. Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. Cancer Immunol Res. 2020 02; 8(2):192-202.
    View in: PubMed
    Score: 0.170
  2. Cancer. Awakening immunity. Science. 2010 Nov 05; 330(6005):761-2.
    View in: PubMed
    Score: 0.091
  3. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J Exp Med. 1990 Apr 01; 171(4):1205-20.
    View in: PubMed
    Score: 0.087
  4. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest. 2008 Apr; 118(4):1398-404.
    View in: PubMed
    Score: 0.076
  5. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8633-8.
    View in: PubMed
    Score: 0.041
  6. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens. 1996 May; 47(5):399-407.
    View in: PubMed
    Score: 0.033
  7. Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors. Ann N Y Acad Sci. 1993 Aug 12; 690:244-55.
    View in: PubMed
    Score: 0.027
  8. CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes. Transplantation. 1993 Jun; 55(6):1349-55.
    View in: PubMed
    Score: 0.027
  9. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med. 1992 Jan 01; 175(1):139-46.
    View in: PubMed
    Score: 0.025
  10. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res. 1990 Jul 01; 50(13):3851-8.
    View in: PubMed
    Score: 0.022
  11. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med. 1989 Jul 01; 170(1):217-32.
    View in: PubMed
    Score: 0.021
  12. Unique tumor-specific antigens. Annu Rev Immunol. 1988; 6:465-83.
    View in: PubMed
    Score: 0.019
  13. Identification of a gene encoding a tumor-specific antigen that causes tumor rejection. Haematol Blood Transfus. 1987; 31:308-13.
    View in: PubMed
    Score: 0.017
  14. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004 Feb; 5(2):141-9.
    View in: PubMed
    Score: 0.014
  15. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med. 2003 Apr 21; 197(8):985-95.
    View in: PubMed
    Score: 0.013
  16. Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol. 1999 Oct; 15(4):769-73.
    View in: PubMed
    Score: 0.011
  17. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation. 1993 Jun; 55(6):1356-61.
    View in: PubMed
    Score: 0.007
  18. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science. 1988 Oct 28; 242(4878):569-71.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.